

Figure S1




Figure S1. LongPASS TSS/PAS clustering and validation, related to Fig.1. (A) Workflow for longPASS clustering TSS/PAS from long-read sequencing data. **(details see methods).** **(B-C).** Correlation between annotated and longPASS-defined TSS/PAS expression of RNA sequins (left panel mix A, Pearson correlation coefficient = 0.8(B); right panel mix B, Pearson correlation coefficient = 0.82(C)). **(D).** Correlation between input TSS/PAS TPM and TSS/PAS TPM identified by longPASS in *NanoSim* simulated data. and longPASS-defined isoform expression of RNA sequins (mix B, Pearson correlation coefficient = 0.88). **(E).** Correlation between annotated and longPASS-defined isoform expression of RNA sequins (mix B, Pearson correlation coefficient = 0.88). **(F, G)** Distance between TSS(F) and PAS(G) defined by longPASS and other long-read analysis methods to CAGE-detected TSS or QuantSeq detected PAS. **(H, I, J, K)** Sensitivity of longPASS Versus Other Long-Read Analysis Methods in Identifying CAGE-defined TSSs **(H)**, CAGE-defined unannotated TSSs **(I)**, QuantSeq-defined PASs **(J)**, QuantSeq-defined unannotated PASs **(K)**. **(L)** Comparison of CPE signal enrichment within ± 100 bp regions surrounding PASs defined by longPASS or from the reference genome **(M)**. Nucleotide composition around reference genome (Gencode v38) annotated TSS/PAS. **(N)** Nucleosome density revealed by MNase-Seq around longPASS-defined TSS/PAS. Shaded area represents nucleosome free region (NFR).

Figure S2




Figure S2. LongPASS helps isoform definition, related to Fig.1. (A) Diagram showing construction of spTIFs by linking longPASS-defined TSS and PAS. **(B)** Classification and proportion of longPASS-defined spTIFs, according to comparison with the gencode annotation transcripts. **(C)** Correlation between TIF-Seq2 defined and longPASS-defined spTIF log2 count per gene (Pearson correlation coefficient =0.55). **(D)** UIC consistence of FulQuant compared to other methods across different long-read protocols. **(E, F)** Sensitivity of isoform detection in WTC11-Induced human iPCs by integrating longPASS and FulQuant compared to other Methods: Annotated Isoforms **(E)**, Novel Isoforms **(F)**

Figure S3




Figure S3. TASEs exhibit distinct characteristics compared to controls, related to Fig.2. (A). Number of regions detected in this analysis and testable regions for TASE coupling test. **(B).** Statistics of identified TASE pairs and associated gene count. **(C)** Differential expression of Exons (TASEs vs Control) in Ribo-seq vs. total mRNA-seq data ('Up' indicates exons with significantly higher ribosome levels relative to transcriptional levels, opposite relationship labeled 'Down'). **(D)** Exon inclusion variance across 49 tissues (GTEx), TASE (n = 3,154) versus Control (n = 12,000), $*P = 0.011$, P value from two-tailed Mann-Whitney test. **(E)** Diagram showing steps for distinguishing Exon-in TASEs and Exon-out TASEs. **(F).** Statistics of TASE type associated with each TASE exon (Exon-in-TSS/PAS, Exon-out-TSS/PAS). **(H-I)** Transcription factors that show differential binding signal around different types of TSS. **(J-K).** The proportion of spatially interacting TSS-exon pairs (J) or PAS-exon pairs (K) from different groups revealed by RIC-Seq with different library method.

Figure S4




Figure S4. TASE is a pervasive way of gene regulation, related to Fig.3. (A) Correlation distribution of TASE TSS-Exon pairs in all tissues, and individual tissues (Liver, Brain-cortex, Muscle-skeletal). **(B)** Correlation distribution of TASE Exon-PAS pairs in all tissues, and individual tissues (Liver, Brain-cortex, and Muscle-skeletal). **(C).** Comparing the expression correlation of different kinds of TASE Exon-PAS pairs across 49 different tissues. **(D)** Comparing the expression correlation of different kinds of TASE Exon-PAS pairs across 838 different human individuals. **(E)** Correlation distribution of TASE Exon-PAS pairs in ILC2 cell and NK cell.

Figure S5




Figure S5. Knocking down RBMX impacts TASE co-regulation, related to Fig.4. (A) The expression of genes in RBMX knock-down experiment vs. control. **(B-C)** The Calculation of PREITI and PREOTI. **(D)** The comparison of PREITI (Percentage of Exon-in-TASE isoform Index) for Exon-in-PAS-TASEs in RBMX knock-down (RBMX-KD) and WT cells. PREITI significantly ($|\text{PREITI}| > 0.1$, $P < 0.001$) increased cases are colored red, and decreased cases are colored blue. **(E)** Boxplot of PREITI scores for significant Exon-in-PAS-TASE in (D) of RBMX knock-down and WT cells. **(F)** The density distribution of delta PREITIs between RBMX-KD and WT for up-regulated Exon-in-PAS TASE pairs (red) and non-TASE controls (grey). **(G).** The alignment of raw long reads of Exon-in and Exon-out-PAS-TASE isoforms from the *PRR3* gene in RBMX-KD and WT cells, Exon-in: $***P < 3.9e-4$, Exon-out: $*P < 0.0413$. P from two-proportions z-test and FDR correction applied. **(H).** The alignment of raw long reads of Exon-in and Exon-out-PAS-TASE isoforms in *LINC02780* gene for RBMX-KD and WT cells. **(I-J).** The proportion of long reads of TASE Exon-in and Exon-out isoforms in *PRR3* gene **(I)** and *LINC02780* and *LINC02780* gene **(J)** for RBMX-KD and WT cells. **(K)** Proportional Distribution of Significant Alternative Splicing Event Types Identified by SUPPA (A5: alternative 5'SS, A3: alternative 3'SS, AF: alternative first exon, AL: alternative last exon, MX: mutual exclusive exon, RI: Intron retention, SE: exon skipping). **(L)** Proportion of TASE Exons Overlapping with Significantly Skipped Exons Under Each KD Condition. **(M)** Comparison of PREITI of Exon-in-PAS-TASEs ($n=1963$) between U2AF2-KD and WT cells. Significant PREITI ($|\text{PREITI}| > 0.07$, $P < 0.001$) increases are colored red and decreases are colored blue. **(N)** Boxplot of PREITIs for significant Exon-in-PAS-TASEs in U2AF2-KD and WT cells. **(O)** Change in PREITI (ΔPREITI) of Significant Exon-in PAS TASE Events Compared to WT Across Different Knockdown Conditions. **(P)** The m6A signals around acceptor and donor splice sites of PAS-TASE ($n=2148$) and control exons ($n=12000$).

Figure S6




Figure S6. Altered Pol II elongation rate impacts TASE co-regulation, related to Fig.5. (A). Sanger-Seq demonstrating mutation (R749H, E1126G) on associated 293T Pol II mutant. **(B)** Validating the Pol II elongation speed of each mutant using nascent RNA methods (P: proximal region, D: distal region; P/D are used to evaluate elongation rate), measured by qPCR, conducted with three technical replicates. **(C)** ONT raw reads of PAS-TASE case of *DUXAP9* in Exo-ctrl, Exo-slow, DMSO and Ama. **(D)** Statistics of TASE-related region expression of *DUXAP9* in Exo-ctrl, Exo-slow, DMSO and Ama (each $n = 2$). **(E-F)**. Comparison of PoleSen-PAS and non-TASE PAS between proliferating state and senescent state of HUVECs.